Viking offers asymmetric upside in GLP-1 drugs with positive trial data, strong cash, and buyout potential despite biotech ...

At the end of Q2, the biotech has a cash balance of $808 million and burned $95 million in the 1H of the year. Viking ...

Viking Therapeutics, Inc. (VKTX) ended the recent trading session at $23.94, demonstrating a +1.44% swing from the preceding day's closing price. The stock outperformed the S&P 500, which registered a ...

Viking Therapeutics presents a high-risk, high-reward opportunity in the exploding GLP-1 weight loss market, where early clinical data for its VK2735 drug shows competitive results against current ...

A second analyst voices positive thoughts on Viking's new GLP-1 weight loss drug. Phase 3 clinical trial data on VK2735 arrives later this year, and phase 2 data on a GLP-1 pill could come out as ...

Viking Therapeutics (NASDAQ: VKTX) suffered a brutal market sell-off on Tuesday, with shares plunging over 40% in one of the biotech firm's steepest single-day drops since its initial public offering ...

Viking Therapeutics is developing drugs for obesity and non-alcoholic fatty liver disease. The company has no revenue and may have none for several years as it works to get drug approval. Viking could ...

Financial giants have made a conspicuous bullish move on Viking Therapeutics. Our analysis of options history for Viking Therapeutics VKTX revealed 12 unusual trades. Delving into the details, we ...